Risankizumab clinical trials
Risankizumab is named as an intervention in 21 current clinical trials in our USA, Canada, Poland, UK, Germany, Spain, Italy, France, Czechia, China, Belgium, Israel, Netherlands, South Korea, Taiwan, Sweden, Japan, Denmark, Switzerland, Austria, Brazil, Portugal, Turkey, Singapore, Australia, Mexico, Ireland, Norway and Egypt registers. 11 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is AbbVie (16). The most-studied condition is Crohn's Disease.
Where Risankizumab is approved
All regulators →Of the three regulators tracked here, the first to approve Risankizumab was Canada, on 17 Apr 2019. It is approved in 3 of the 3 regulators tracked here.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
What health systems spend on Risankizumab
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Risankizumab works
All drug targets →- Interleukin-23 inhibitor InhibitorTarget: Interleukin-23ChEMBL only
- Generalized pustular psoriasisPhase 3
- Intestinal obstructionPhase 3
- Palmoplantar pustulosisPhase 3
- Psoriasis-related juvenile idiopathic arthritisPhase 3
- COVID-19Phase 2
- Ankylosing spondylitisPhase 2
- AsthmaPhase 2
- Atopic eczemaPhase 2
- Hidradenitis suppurativaPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL3990029, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 8922, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
NICE appraisals of Risankizumab
All NICE appraisals →NICE, which decides whether the NHS in England should fund new medicines, has published 4 technology appraisals of Risankizumab. 4 are current, and 4 of these recommend it for at least some patients.
| Appraisal | NICE recommendation | Published | Status |
|---|---|---|---|
| Risankizumab for treating moderately to severely active ulcerative colitis NICE TA998 | Optimised | 22 Aug 2024 | Current |
| Risankizumab for previously treated moderately to severely active Crohn's disease NICE TA888 | Optimised | 17 May 2023 | Current |
| Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs NICE TA803 | Optimised | 13 Jul 2022 | Current |
| Risankizumab for treating moderate to severe plaque psoriasis NICE TA596 | Recommended | 21 Aug 2019 | Current |
NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
Patient leaflets for Risankizumab
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 9 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- EUEuropean Union: SkyriziEMA product information: package leaflet and summary of product characteristics in every EU language.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Risankizumab
21 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Risankizumab across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
9 single-substance products containing Risankizumab on the HPRA medicines list.
- Skyrizi 150 mg Solution for injectionAbbVie Deutschland GmbH & Co. KG · EU/1/19/1361/003
- Skyrizi 150 mg Solution for injectionAbbVie Deutschland GmbH & Co. KG · EU/1/19/1361/002
- Skyrizi 180 mg Solution for injectionAbbVie Deutschland GmbH & Co. KG · EU/1/19/1361/007
- Skyrizi 180 mg solution for injection in pre-filled syringeAbbVie Deutschland GmbH & Co. KG · EU/1/19/1361/008-009
- Skyrizi 360 mg Solution for injectionAbbVie Deutschland GmbH & Co. KG · EU/1/19/1361/005
Supply shortages
No entry for Risankizumab in the EMA, FDA or German BfArM shortage lists we track.
Conditions studied with Risankizumab
15 conditionsAll 15 conditions
| Condition (as registered) | Trials |
|---|---|
| Crohn's Disease | 6 |
| Ulcerative Colitis | 3 |
| Crohn Disease | 3 |
| Psoriatic Arthritis | 2 |
| Psoriasis | 1 |
| Juvenile Psoriatic Arthritis | 1 |
| Crohn's Disease (CD) | 1 |
| Arthritis, Psoriatic | 1 |
| Psoriatic Arthritis (PsA) | 1 |
| Ulcerative Colitis (UC) | 1 |
| Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment | 1 |
| Healthy Volunteer | 1 |
| Perianal Fistula | 1 |
| Perianal Fistula Due to Crohn's Disease | 1 |
| Perianal Crohn's Disease | 1 |
Sponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| AbbVie | 16 |
| Janssen Research & Development, LLC | 1 |
| MoonLake Immunotherapeutics AG | 1 |
| Universitaire Ziekenhuizen KU Leuven | 1 |
| Alimentiv Inc | 1 |
| Yuki Horio | 1 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Risankizumab trials
How many clinical trials are testing Risankizumab?
21 current trials in our USA, Canada, Poland, UK, Germany, Spain, Italy, France, Czechia, China, Belgium, Israel, Netherlands, South Korea, Taiwan, Sweden, Japan, Denmark, Switzerland, Austria, Brazil, Portugal, Turkey, Singapore, Australia, Mexico, Ireland, Norway and Egypt registers name Risankizumab (also registered as ABBV-066) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Risankizumab trials recruiting patients?
Yes. 11 of the 21 trials are recruiting: 9 with sites in USA, 7 with sites in Canada, 6 with sites in Poland, 5 with sites in UK, 5 with sites in Germany, 5 with sites in Spain, 6 with sites in Italy, 5 with sites in France, 4 with sites in Czechia, 5 with sites in China, 5 with sites in Belgium, 3 with sites in Israel, 3 with sites in Netherlands, 3 with sites in South Korea, 4 with sites in Taiwan, 3 with sites in Sweden, 4 with sites in Japan, 2 with sites in Denmark, 2 with sites in Switzerland, 2 with sites in Austria, 1 with sites in Brazil, 1 with sites in Portugal, 2 with sites in Turkey, 1 with sites in Singapore, 1 with sites in Australia, 1 with sites in Ireland and 1 with sites in Norway. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Risankizumab clinical trials?
AbbVie (16), Janssen Research & Development, LLC (1), MoonLake Immunotherapeutics AG (1) and Universitaire Ziekenhuizen KU Leuven (1), among 6 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Are there Risankizumab clinical trials in Ireland?
Yes. 3 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Is Risankizumab licensed in Ireland?
Yes. The HPRA medicines list includes 9 single-substance products containing Risankizumab, for example Skyrizi 150 mg Solution for injection (AbbVie Deutschland GmbH & Co. KG). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Risankizumab shortage?
Not in the lists we track: Risankizumab has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Risankizumab works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Risankizumab works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Risankizumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.